Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
88 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | active not recruiting | Phase 1 | 520 | AbbVieINDUSTRY | 10 | Oct 29, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 |
| clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06351527 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | recruiting | Phase 1 | 78 | InnoCare Pharma Inc.INDUSTRY | 3 | Jun 19, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
| NCT03649971 | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | completed | Phase 1 | 77 | Janssen Research & Development, LLCINDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT03278925 | Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis | unknown | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 2 | Aug 2, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT05014360 | A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis | completed | Phase 1 | 42 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 2, 2023 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT01188850 | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 | completed | Phase 1 | 14 | Inovio PharmaceuticalsINDUSTRY | 2 | Aug 10, 2018 | clinicaltrials |
| NCT00098839 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 134 | Children's Oncology GroupNETWORK | 4 | Dec 12, 2017 | clinicaltrials |
| NCT00649207 | A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases | completed | Phase 1 | 80 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Nov 21, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT00685412 | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 | completed | Phase 1 | 18 | Inovio PharmaceuticalsINDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT00006029 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 91 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT01489059 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | completed | Phase 1 | 42 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 29, 2014 | clinicaltrials |
| NCT00003625 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma | completed | Phase 1 | 7 | Children's Oncology GroupNETWORK | 5 | Jul 28, 2014 | clinicaltrials |
| NCT00003935 | Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma | completed | Phase 1 | 31 | Children's Oncology GroupNETWORK | 6 | Jul 28, 2014 | clinicaltrials |
| NCT00742924 | Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma | completed | Phase 1 | 24 | Children's Oncology GroupNETWORK | 4 | Jul 4, 2014 | clinicaltrials |
| NCT00004932 | STI571 in Treating Patients With Recurrent Leukemia | completed | Phase 1 | 31 | Children's Oncology GroupNETWORK | 7 | Feb 21, 2014 | clinicaltrials |
| NCT00006024 | Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma | completed | Phase 1 | 32 | Children's Oncology GroupNETWORK | 7 | Feb 13, 2014 | clinicaltrials |
| NCT00009698 | Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia | completed | Phase 1 | 1 | Children's Oncology GroupNETWORK | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00002705 | Topotecan in Treating Children With Refractory Leukemia | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 4 | Feb 1, 2013 | clinicaltrials |
| NCT01527422 | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL(CHOP-R) | completed | Phase 1 / Phase 2 | 60 | Fernando CabanillasOTHER | 1 | Feb 7, 2012 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials